10,773 Amgen Inc. $AMGN Shares Sold by Novem Group

Novem Group lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 72.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,128 shares of the medical research company’s stock after selling 10,773 shares during the period. Novem Group’s holdings in Amgen were worth $1,740,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Sterling Investment Counsel LLC boosted its holdings in Amgen by 3.4% in the third quarter. Sterling Investment Counsel LLC now owns 952 shares of the medical research company’s stock worth $401,000 after acquiring an additional 31 shares in the last quarter. Clark Financial Services Group Inc. BD increased its holdings in shares of Amgen by 17.6% during the third quarter. Clark Financial Services Group Inc. BD now owns 1,561 shares of the medical research company’s stock valued at $658,000 after acquiring an additional 234 shares in the last quarter. Hidden Cove Wealth Management LLC increased its holdings in shares of Amgen by 5.0% during the third quarter. Hidden Cove Wealth Management LLC now owns 1,437 shares of the medical research company’s stock valued at $606,000 after acquiring an additional 68 shares in the last quarter. Greg Jennings LLC acquired a new position in shares of Amgen during the third quarter valued at about $2,424,000. Finally, Crown Wealth Group LLC raised its position in shares of Amgen by 3.6% in the 3rd quarter. Crown Wealth Group LLC now owns 1,072 shares of the medical research company’s stock valued at $452,000 after purchasing an additional 37 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Activity

In other news, SVP Rachna Khosla sold 1,252 shares of the business’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at $2,666,817.72. The trade was a 16.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Nancy A. Grygiel sold 2,970 shares of the company’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. The trade was a 28.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 6,222 shares of company stock worth $2,540,926 over the last ninety days. 0.85% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of analysts recently commented on AMGN shares. Barclays lifted their target price on shares of Amgen from $360.00 to $380.00 and gave the stock an “equal weight” rating in a research note on Friday, August 14th. Mizuho raised their price target on shares of Amgen from $303.00 to $352.00 and gave the stock a “neutral” rating in a report on Tuesday, August 18th. Jefferies Financial Group reiterated a “hold” rating and set a $410.00 price objective on shares of Amgen in a research note on Wednesday, September 23rd. Scotiabank lifted their price objective on shares of Amgen from $450.00 to $500.00 and gave the stock an “outperform” rating in a research note on Monday, September 28th. Finally, UBS Group boosted their price objective on shares of Amgen from $430.00 to $470.00 and gave the company a “buy” rating in a report on Friday, October 9th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $387.93.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Australia’s Pharmaceutical Benefits Advisory Committee conditionally backed coverage for Imdelltra, Amgen’s treatment for small-cell lung cancer. A reimbursement decision could improve patient access and support future sales, although the conditional nature leaves implementation and approval details unresolved. PBAC conditionally backs Imdelltra
• Positive Sentiment: Exchange-traded funds reportedly purchased approximately $19.4 million of Amgen shares on October 15, indicating institutional demand and potentially providing technical support. Such flows are supportive but do not change the company’s underlying earnings outlook. ETFs Bought $19.4 Million of Amgen
• Neutral Sentiment: Several reports highlight Amgen’s broad portfolio, dividend, and potential growth from newer therapies. Zacks coverage mainly reflects increased investor attention rather than a new operational catalyst or change in estimates. Amgen: The Biotech Pioneer Preparing for Its Next Growth Wave
• Negative Sentiment: Analysts and market commentary emphasize that Amgen now needs stronger growth to justify its valuation. Mature products generate dependable cash flow and support the dividend, but investors are looking for faster expansion from newer drugs, making pipeline execution and commercial uptake key risks. Amgen Has the Drugs and the Dividend

Amgen Stock Performance

NASDAQ:AMGN traded down $7.55 during midday trading on Monday, hitting $424.94. The company’s stock had a trading volume of 2,681,575 shares, compared to its average volume of 2,758,142. Amgen Inc. has a fifty-two week low of $288.00 and a fifty-two week high of $447.03. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. The firm has a market cap of $229.74 billion, a P/E ratio of 26.41, a P/E/G ratio of 3.17 and a beta of 0.41. The firm’s 50 day moving average is $415.69 and its 200-day moving average is $375.45.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating the consensus estimate of $5.62 by $0.67. The business had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same period in the prior year, the firm earned $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities analysts anticipate that Amgen Inc. will post 22.94 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were issued a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend was Friday, August 21st. Amgen’s dividend payout ratio is presently 62.65%.

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.